Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Galenica (SWX:GALN) will acquire Aspreva (TSX:ASV; ASPV) for US$26 per share or about US$915 million in cash. The deal is a 16% premium
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury